Anteris DurAVR THV reports zero PPM at one year in small annuli patients

Anteris Technologies Global Corp.

One-year hemodynamic data: EOA 2.1±0.2 cm², mean gradient 8.6±2.6 mmHg, DVI 0.58 (n=65).
Zero prosthesis-patient mismatch (PPM) in small annuli patients; commercial valves report 11-35% PPM.
No valve or cardiovascular related mortality at one year; consistent safety profile.
Data to support planned IDE submission to FDA for DurAVR THV pivotal study.
Results presented at Sydney Valves late-breaking clinical trial session on March 21, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.